NCT02625714已完成1 期
A Randomized, Open-label, Oral Multiple Dosing, Two-way Crossover Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Profiles of SID142 in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 41
- 主要终点
- AUC[Area under the concentration curve]τ,ss of Cilostazol
研究概览
简要总结
A randomized, open-label, oral multiple dosing, two-part, two-way crossover clinical trial to evaluate the safety/tolerability and pharmacokinetic profiles of SID142 in healthy volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult aged between 19 and 45
- •Weights more than 50Kg , BMI between 18.5 and 25.0 kg/m2
- •Subject without congenital or chronic disease requiring medical treatment and any pathological symptoms or opinion according to internal examination
- •Subject with acceptable laboratory result and ECG result
- •Negative result to blood serum human chorionic gonadotropin[hCG] pregnancy test at screening and urine hCG pregnancy test prior to administration in female subject. In addition, at least one condition should be corresponded which is stated below
- •Menopause(no menstruation for at least 2 years)
- •surgically sterile (hysterectomy or both oophorectomy, tubal ligation or other method)
- •Male partner should be sterile(confirmed as aspermia after deferentectomy) and sole before screening.
- •Woman who agreed to use proper method of conception accurately and continuously from at least 14 days before first Investigational Product[IP] administration to at least 30days after dosing.
- •Male subject should use contraception(condom) during clinical trial and maintain contraception and agree not to donate sperm until 28days after last dosing.
- •Subject who was given and completely understood full explanation about the study, decided to participate in the study and signed written informed consent willingly.
排除标准
- •Female subject who is pregnant or breast-feeding
- •Person who has anaphylaxis for IP component or clinically significant medical history of anaphylaxis for other drugs
- •Subject with a clinically significant medical history of disease on liver, kidney, nervous system, respiratory system, endocrine system, blood tumor, urinary system, cardiovascular system, musculoskeletal system or psychiatric disorder or others below
- •severe nephrotic disorder
- •moderate or severe hepatic disorder
- •menstruation period
- •aortocoronary stenosis complication
- •disease or predisposition of bleeding
- •congestive heart failure or arrhythmia
- •diabetes mellitus or glucose tolerance disorder
- •Subject with clinically significant findings on electrocardiogram[ECG] result during screening as stated below
- •QTc > 450 ms
- •PR interval > 200 msec
- •QRS duration > 120 msec
- •Active liver disease or inadequate laboratory result: AST[aspartate aminotransferase] , ALT[alanine aminotransferase] > 1.5 x upper limit of normal range
- •At screening, subject with clinically significant vital signs(sitting position blood pressure): Systolic blood pressure >140 mmHg or < 90 mmHg, diastolic pressure > 90 mmHg or < 60 mmHg
- •Hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome
- •Subject with a presence of gastroenteric disease or history of gastroenteric surgery which can influence the drug absorption
- •Subject who has been seriously injured or received surgery or shown suspicious acute disease symptoms within 4 weeks of first administration.
- •Consumption of excessive alcohol continuously or the subject who cannot quit drinking within 3 days prior to IP administration and during clinical trial period or subject who smokes
- •A history of taking any ETC drugs[Ethical drugs], oriental medicine within 2 weeks or OTC drugs[Over-the-Counter drugs] within 1week prior to first administration
- •Participation in another clinical trial in the previous 3 months before first administration of this study
- •Donation of whole blood in the previous 2 months or apheresis blood in the previous 1 month before first administration
- •The subject with abnormal diet which can influence absorption, distribution, metabolism, and excretion of drug
- •Consumption of food which can influence drug metabolism or caffeine within 48 hours after the first administration, or the subject who cannot quit consumption of such foods during whole study period.
- •Positive results to serum tests (HBsAg[hepatitis B surface antigen], anti-HCV Ab[hepatitis C virus antibody], anti-HIV Ab[human immunodeficiency virus antibody], VDRL[Venereal Disease Research Laboratory] test)
研究组 & 干预措施
A group
Other
Renexin® → SID142
干预措施: Renexin® (Drug)
A group
Other
Renexin® → SID142
干预措施: SID142 (Drug)
B group
Other
SID142 → Renexin®
干预措施: Renexin® (Drug)
B group
Other
SID142 → Renexin®
干预措施: SID142 (Drug)
结局指标
主要结局
AUC[Area under the concentration curve]τ,ss of Cilostazol
时间窗: During 144hours post-dose in each period
Total 68 time points during periods of both 1 and 2
Cmax,ss of Cilostazol
时间窗: During 144hours post-dose in each period
Total 68 time points during periods of both 1 and 2
次要结局
- Tmax,ss of Cilostazol(During 144hours post-dose in each period)
- CL[clearance]SS/F of Cilostazol(During 144hours post-dose in each period)
- AUClast,ss of Cilostazol(During 144hours post-dose in each period)
- T1/2 of Cilostazol(During 144hours post-dose in each period)
- Incidence rate of Adverse Events(During 25days from first administration of period 1)
研究者
相似试验
招募中
1 期
Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy SubjectsDrug Drug InteractionNCT06119958Daewoong Pharmaceutical Co. LTD.32
已完成
1 期
A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male SubjectsBenign Prostatic Hypertrophy (BPH)NCT02615782Chong Kun Dang Pharmaceutical16
已完成
1 期
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.Type 2 Diabetes MellitusNCT06483243Chong Kun Dang Pharmaceutical45
已完成
1 期
Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy SubjectsPharmacokineticsNCT04092751Scynexis, Inc.28
已完成
1 期
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).SchizophreniaNCT03370640Sumitomo Pharma Co., Ltd.24